Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – FDA.gov
FDA has authorized marketing of a new device intended for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis
For Immediate Release:
March 26, 2021
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that…
-
Noosa News23 hours agoAustralian growers expect to benefit from US tariffs as Trump’s trade war angers markets
-
Noosa News21 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News23 hours agoHow to get the most from potted citrus and when they’ll fruit
-
General22 hours agoPeter Dutton partially walks back public service work-from-home vow